Amira Pharmaceuticals Inc.
SAN DIEGO, May 11, 2011 - Amira Pharmaceuticals, Inc.
SAN DIEGO, May 2, 2011 - Amira Pharmaceuticals, Inc.
SAN DIEGO, April 19, 2011 - Amira Pharmaceuticals, Inc.
SAN DIEGO, January 5, 2011 - Amira Pharmaceuticals, Inc.
SAN DIEGO, December 15, 2010 - Amira Pharmaceuticals, Inc.
More News
- Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010
- Potential Therapy for Lung Fibrosis of Scleroderma and Idiopathic Pulmonary Fibrosis
- Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
- Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotech's Annual Fierce 15
- Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
- Patent Covers FLAP (5-Lipoxygenase Activating Protein) Inhibitor Licensed to GSK
- Patent Covers Novel DP2 (CRTH2) Receptor Antagonists for the Treatment of Respiratory Disorders
- Anti-Fibrotic Data from Amira Pharmaceuticals' LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
- Patent Covers Novel DP2 (CRTH2) Receptor Antagonists for the Treatment of Respiratory Disorders
- Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
- Amira Pharmaceuticals Achieves Development Milestone Related to FLAP Inhibitor Program
- Results Demonstrate Positive Proof of Mechanism
